Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30562820 | 1.00 | GAA (0.31) | GAAALDH1A1HTTRAD52SNCA | |
| SCHEMBL1567609 | 0.85 | PYCR1 (0.37) | GAAALDH1A1HTTIDO1MAPK1 | |
| SCHEMBL29765549 | 0.85 | PYCR1 (0.37) | GAAALDH1A1HTTIDO1MAPK1 | |
| SCHEMBL31009547 | 0.82 | ALOX15 (0.31) | — | |
| SCHEMBL1567091 | 0.79 | IDO1 (0.52) | ALDH1A1HTTIDO1 | |
| SCHEMBL1567600 | 0.77 | IDO1 (0.47) | GAAALDH1A1HTTIDO1 | |
| SCHEMBL31009548 | 0.75 | — | — | |
| SCHEMBL755548 | 0.74 | PTPN1 (0.39) | ALDH1A1HTTSNCAIDO1 | |
| SCHEMBL31009565 | 0.73 | HTR2A (0.40) | — | |
| SCHEMBL31009556 | 0.73 | ALDH1A1 (0.31) | GAAALDH1A1HTTRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093744-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2072522-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093744-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | SLC5A1, SLC5A2, GCKR | GAA 2712/4885ALDH1A1 1274/4885HTT 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.